Adenocarcinoma and Other Tumors of the Stomach

Sleisenger and Fordtran’s Gastrointestinal and Liver Disease- 2 Volume Set: Pathophysiology, Diagnosis, Management, Expert Consult Premium Edition - Enhanced Online Features and Print

Volumn , Issue , 2010, Pages 887-906

  Abrams, Julian A ^a,b,c   Wang, Timothy C ^a,b  

^a College of Physicians and Surgeons ^*  (United States)

^b NewYork Presbyterian Hospital   (United States)

^c Herbert Irving Comprehensive Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85124856671     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6189-2.00054-8     Document Type: Chapter

References (394)

1. Cunningham D., Allum WH., Stenning SP., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 2006 11-20(Ref 354.)
2. de Vries AC., van Grieken NC., Looman CW., et al. Gastric cancer risk in patients with premalignant gastric lesions: A nationwide cohort study in the Netherlands Gastroenterology 134 2008 945-952(Ref 206.)
3. El-Omar EM., Carrington M., Chow WH., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer Nature 404 2000 398-402(Ref 120.)
4. Fukase K., Kato M., Kikuchi S., et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial Lancet 372 2008 392-397(Ref 249.)
5. Hartgrink HH., van de Velde CJ., Putter H., et al. Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial J Clin Oncol 22 2004 2069-2077(Ref 342.)
6. Kaurah P., MacMillan A., Boyd N., et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer JAMA 297 2007 2360-2372(Ref 133.)
7. Lichtenstein P., Holm NV., Verkasalo PK., et al. Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark, and Finland N Engl J Med 343 2000 78-85(Ref 116.)
8. Macdonald JS., Smalley SR., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 2001 725-730(Ref 355.)
9. McDonald SA., Greaves LC., Gutierrez-Gonzalez L., et al. Mechanisms of field cancerization in the human stomach: The expansion and spread of mutated gastric stem cells Gastroenterology 134 2008 500-510(Ref 14.)
10. Ohnishi N., Yuasa H., Tanaka S., et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse Proc Natl Acad Sci U S A 105 2008 1003-1008(Ref 59.)
11. Plummer M., Vivas J., Lopez G., et al. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: A randomized trial in a high-risk population J Natl Cancer Inst 99 2007 137-146(Ref 260.)
12. Soetikno R., Kaltenbach T., Yeh R., Gotoda T Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract J Clin Oncol 23 2005 4490-4498(Ref 345.)
13. Tu S., Bhagat G., Cui G., et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice Cancer Cell 14 2008 408-419(Ref 127.)
14. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of gastric cancer N Engl J Med 345 2001 784-789(Ref 27.)
15. Wong BC., Lam SK., Wong WM., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial JAMA 291 2004 187-194(Ref 246.)
16. Global burden of disease (GBD), 2002 estimates World Health Organization, 2008. Accessed July 11, 2008, atwww.who.int/healthinfo/bodgbd2002/en/index.html.
17. IARC World Cancer Report International Agency for Research on Cancer, 2006. Accessed July 11, 2008, atwww.iarc.fr/IARCPress/pdfs/wcr/index.php.
18. Crew KD., Neugut AI Epidemiology of gastric cancer World J Gastroenterol 12 2006 354-362.
19. Summary of changes in cancer mortality, 1950-2005 National Cancer Institute, 2008. Accessed July 11, 2008, athttp://seer.cancer.gov/cgi-bin/csr/1975_2005.
20. Age-Adjusted SEER Incidence and US Death Rates and 5-Year Relative Survival Rates National Cancer Institute, 2008. Accessed athttp://seer.cancer.gov/cgi-bin/csr/1975_2005.
21. Parkin DM International variation Oncogene 23 2004 6329-6340.
22. Estimated new cancer cases and deaths for 2008 National Cancer Institute, 2008. Accessed July 11, 2008, athttp://seer.cancer.gov/cgi-bin/csr/1975_2005.
23. SEER cancer stat fact sheets: Cancer of the stomach National Cancer Institute, 2008. Accessed athttp://seer.cancer.gov/statfacts/html/stomach.html.
24. Wiggins CL., Becker TM., Key CR., Samet JM Stomach cancer among New Mexico’s American Indians, Hispanic whites, and non-Hispanic whites Cancer Res 49 1989 1595-1599.
25. Wanebo HJ., Kennedy BJ., Chmiel J., et al. Cancer of the stomach. A patient care study by the American College of Surgeons Ann Surg 218 1993 583-592.
26. Locke GR 3rd., Talley NJ., Carpenter HA., et al. Changes in the site-and histology-specific incidence of gastric cancer during a 50-year period Gastroenterology 109 1995 1750-1756.
27. Munoz N., Correa P., Cuello C., Duque E Histologic types of gastric carcinoma in high-and low-risk areas Int J Cancer 3 1968 809-818.
28. Fearon ER Molecular genetics of colorectal cancer Ann N Y Acad Sci 768 1995 101-110.
29. McDonald SA., Greaves LC., Gutierrez-Gonzalez L., et al. Mechanisms of field cancerization in the human stomach: The expansion and spread of mutated gastric stem cells Gastroenterology 134 2008 500-510.
30. Munoz N., Matko I Histological types of gastric cancer and its relationship with intestinal metaplasia Recent Results Cancer Res 39 1972 99-105.
31. Correa P Human gastric carcinogenesis: A multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention Cancer Res 52 1992 6735-6740.
32. Correa P., Haenszel W., Cuello C., et al. Gastric precancerous process in a high risk population: Cohort follow-up Cancer Res 50 1990 4737-4740.
33. Cai X., Carlson J., Stoicov C., et al. Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice Gastroenterology 128 2005 1937-1952.
34. Lee CW., Rickman B., Rogers AB., et al. Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice Cancer Res 68 2008 3540-3548.
35. Jiang L., Gonda TA., Gamble MV., et al. Global hypomethylation of genomic DNA in cancer-associated myofibroblasts Cancer Res 2009 (in press).
36. Everhart JE Recent developments in the epidemiology of Helicobacter pylori Gastroenterol Clin North Am 29 2000 559-578.
37. Ernst PB., Gold BD The disease spectrum of Helicobacter pylori: The immunopathogenesis of gastroduodenal ulcer and gastric cancer Annu Rev Microbiol 54 2000 615-640.
38. Amieva MR., El-Omar EM Host-bacterial interactions in Helicobacter pylori infection Gastroenterology 134 2008 306-323.
39. Ahmed A., Smoot D., Littleton G., et al. Helicobacter pylori inhibits gastric cell cycle progression Microbe Infect 2 2000 1159-1169.
40. Suganuma M., Kurusu M., Okabe S., et al. Helicobacter pylori membrane protein 1: A new carcinogenic factor of Helicobacter pylori Cancer Res 61 2001 6356-6359.
41. Baik SC., Youn HS., Chung MH., et al. Increased oxidative DNA damage in Helicobacter pylori-infected human gastric mucosa Cancer Res 56 1996 1279-1282.
42. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of gastric cancer N Engl J Med 345 2001 784-789.
43. Hsu PI., Lai KH., Hsu PN., et al. Helicobacter pylori infection and the risk of gastric malignancy Am J Gastroenterol 102 2007 725-730.
44. Kamangar F., Qiao YL., Blaser MJ., et al. Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China Br J Cancer 96 2007 172-176.
45. Kamangar F., Dawsey SM., Blaser MJ., et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity J Natl Cancer Inst 98 2006 1445-1452.
46. Williams CS., Smalley W., DuBois RN Aspirin use and potential mechanisms for colorectal cancer prevention J Clin Invest 100 1997 1325-1329.
47. Meira LB., Bugni JM., Green SL., et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice J Clin Invest 118 2008 2516-2525.
48. Mandell L., Moran AP., Cocchiarella A., et al. Intact gram-negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4 Infect Immun 72 2004 6446-6454.
49. Raghavan S., Nystrom J., Fredriksson M., et al. Orally administered CpG oligodeoxynucleotide induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of Helicobacter pylori infection Infect Immun 71 2003 7014-7022.
50. Kawahara T., Kuwano Y., Teshima-Kondo S., et al. Helicobacter pylori lipopolysaccharide from type I, but not type II strains, stimulates apoptosis of cultured gastric mucosal cells J Med Invest 48 2001 167-174.
51. Kawahara T., Teshima S., Oka A., et al. Type I Helicobacter pylori lipopolysaccharide stimulates toll-like receptor 4 and activates mitogen oxidase 1 in gastric pit cells Infect Immun 69 2001 4382-4389.
52. Smith MF Jr., Mitchell A., Li G., et al. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells J Biol Chem 278 2003 32552-32560.
53. Wang TC., Goldenring JR., Dangler C., et al. Mice lacking secretory phospholipase A2 show altered apoptosis and differentiation with Helicobacter felis infection Gastroenterology 114 1998 675-689.
54. Sutton P., Kolesnikow T., Danon S., Wilson J., Lee A Dominant nonresponsiveness to Helicobacter pylori infection is associated with production of interleukin 10 but not gamma interferon Infect Immun 68 2000 4802-4804.
55. Eaton KA., Mefford M., Thevenot T The role of T cell subsets and cytokines in the pathogenesis of Helicobacter pylori gastritis in mice J Immunol 166 2001 7456-7461.
56. Roth KA., Kapadia SB., Martin SM., Lorenz RG Cellular immune responses are essential for the development of Helicobacter felis-associated gastric pathology J Immunol 163 1999 1490-1497.
57. Fox JG., Sheppard BJ., Dangler CA., et al. Germ-line p53-targeted disruption inhibits Helicobacter-induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 proinflammatory responses Cancer Res 62 2002 696-702.
58. Smythies LE., Waites KB., Lindsey JR., et al. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice J Immunol 165 2000 1022-1029.
59. Ernst M., Najdovska M., Grail D., et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice J Clin Invest 118 2008 1727-1738.
60. Fox JG., Beck P., Dangler CA., et al. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces Helicobacter-induced gastric atrophy Nat Med 6 2000 536-542.
61. Segal I., Ally R., Mitchell H Helicobacter pylori-An African perspective QJM 94 2001 561-565.
62. Whary MT., Sundina N., Bravo LE., et al. Intestinal helminthiasis in Colombian children promotes a Th2 response to Helicobacter pylori: Possible implications for gastric carcinogenesis Cancer Epidemiol Biomarkers Prev 14 2005 1464-1469.
63. Blaser MJ., Berg DE Helicobacter pylori genetic diversity and risk of human disease J Clin Invest 107 2001 767-773.
64. Israel DA., Salama N., Krishna U., et al. Helicobacter pylori genetic diversity within the gastric niche of a single human host Proc Natl Acad Sci U S A 98 2001 14625-14630.
65. Tomb JF., White O., Kerlavage AR., et al. The complete genome sequence of the gastric pathogen Helicobacter pylori Nature 388 1997 539-547.
66. Kostrzynska M., Betts JD., Austin JW., Trust TJ Identification, characterization, and spatial localization of two flagellin species in Helicobacter pylori flagella J Bacteriol 173 1991 937-946.
67. Kavermann H., Burns BP., Angermuller K., et al. Identification and characterization of Helicobacter pylori genes essential for gastric colonization J Exp Med 197 2003 813-822.
68. Necchi V., Candusso ME., Tava F., et al. Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by Helicobacter pylori Gastroenterology 132 2007 1009-1023.
69. Oliveira AG., Santos A., Guerra JB., et al. babA2-and cagA-positive Helicobacter pylori strains are associated with duodenal ulcer and gastric carcinoma in Brazil J Clin Microbiol 41 2003 3964-3966.
70. Crabtree JE., Taylor JD., Wyatt JI., et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology Lancet 338 8763 1991 332-335.
71. Kuipers EJ., Perez-Perez GI., Meuwissen SG., Blaser MJ Helicobacter pylori and atrophic gastritis: importance of the cagA status J Natl Cancer Inst 87 23 1995 1777-1780.
72. Blaser MJ., Perez-Perez GI., Kleanthous H., et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach Cancer Res 55 1995 2111-2115.
73. Parsonnet J., Friedman GD., Orentreich N., Vogelman H Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection Gut 40 1997 297-301.
74. Ohnishi N., Yuasa H., Tanaka S., et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse Proc Natl Acad Sci U S A 105 2008 1003-1008.
75. Sharma SA., Tummuru MK., Miller GG., Blaser MJ Interleukin-8 response of gastric epithelial cell lines to Helicobacter pylori stimulation in vitro Infect Immun 63 1995 1681-1687.
76. Tummuru MK., Sharma SA., Blaser MJ Helicobacter pylori picB, a homologue of the Bordetella pertussis toxin secretion protein, is required for induction of IL-8 in gastric epithelial cells Mol Microbiol 18 1995 867-876.
77. Glocker E., Lange C., Covacci A., Bereswill S., Kist M., Pahl HL Proteins encoded by the cag pathogenicity island of Helicobacter pylori are required for NF-kappaB activation Infect Immun 66 1998 2346-2348.
78. Peek RM Jr., Miller GG., Tham KT., et al. Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains Lab Invest 73 1995 760-770.
79. Yamaoka Y., Kita M., Kodama T., et al. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa Gastroenterology 110 1996 1744-1752.
80. Ogura K., Maeda S., Nakao M., et al. Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbil J Exp Med 192 2000 1601-1610.
81. Israel DA., Salama N., Arnold CN., et al. Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses J Clin Invest 107 2001 611-620.
82. Gebert B., Fischer W., Weiss E., et al. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation Science 301 2003 1099-1102.
83. Peek RM Jr., Blaser MJ Helicobacter pylori and gastrointestinal tract adenocarcinomas Nat Rev Cancer 2 2002 28-37.
84. Hansson LE., Engstrand L., Nyren O., et al. Helicobacter pylori infection: Independent risk indicator of gastric adenocarcinoma Gastroenterology 105 1993 1098-1103.
85. Larsson SC., Bergkvist L., Wolk A Processed meat consumption, dietary nitrosamines and stomach cancer risk in a cohort of Swedish women Int J Cancer 119 2006 915-919.
86. Bartsch H N-nitroso compounds and human cancer: Where do we stand? IARC Sci Publ 1991 1-10.
87. Mowat C., Carswell A., Wirz A., McColl KE Omeprazole and dietary nitrate independently affect levels of vitamin C and nitrite in gastric juice Gastroenterology 116 1999 813-822.
88. Oldreive C., Rice-Evans C The mechanisms for nitration and nitrotyrosine formation in vitro and in vivo: Impact of diet Free Radic Res 35 2001 215-231.
89. Sugimura T., Fujimura S., Baba T Tumor production in the glandular stomach and alimentary tract of the rat by N-methyl-N′-nitro-N-nitrosoguanidine Cancer Res 30 1970 455-465.
90. Bartsch H., Ohshima H., Pignatelli B., Calmels S Human exposure to endogenous N-nitroso compounds: Quantitative estimates in subjects at high risk for cancer of the oral cavity, oesophagus, stomach and urinary bladder Cancer Surv 8 1989 335-362.
91. Knekt P., Jarvinen R., Dich J., Hakulinen T Risk of colorectal and other gastro-intestinal cancers after exposure to nitrate, nitrite and N-nitroso compounds: A follow-up study Int J Cancer 80 1999 852-856.
92. Jakszyn P., Bingham S., Pera G., et al. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study Carcinogenesis 27 2006 1497-1501.
93. van Loon AJ., Botterweck AA., Goldbohm RA., et al. Intake of nitrate and nitrite and the risk of gastric cancer: A prospective cohort study Br J Cancer 78 1998 129-135.
94. Fox JG., Dangler CA., Taylor NS., et al. High-salt diet induces gastric epithelial hyperplasia and parietal cell loss, and enhances Helicobacter pylori colonization in C57BL/6 mice Cancer Res 59 1999 4823-4828.
95. Ramon JM., Serra L., Cerdo C., Oromi J Dietary factors and gastric cancer risk. A case-control study in Spain Cancer 71 1993 1731-1735.
96. Nazario CM., Szklo M., Diamond E., et al. Salt and gastric cancer: A case-control study in Puerto Rico Int J Epidemiol 22 1993 790-797.
97. Gonzalez CA., Jakszyn P., Pera G., et al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC) J Natl Cancer Inst 98 2006 345-354.
98. Loh JT., Torres VJ., Cover TL Regulation of Helicobacter pylori cagA expression in response to salt Cancer Res 67 2007 4709-4715.
99. Gamboa-Dominguez A., Ubbelohde T., Saqui-Salces M., et al. Salt and stress synergize H. pylori-induced gastric lesions, cell proliferation, and p21 expression in Mongolian gerbils Dig Dis Sci 52 2007 1517-1526.
100. Kobayashi M., Tsubono Y., Sasazuki S., et al. Vegetables, fruit and risk of gastric cancer in Japan: A 10-year follow-up of the JPHC Study Cohort I Int J Cancer 102 2002 39-44.
101. Larsson SC., Bergkvist L., Wolk A Fruit and vegetable consumption and incidence of gastric cancer: A prospective study Cancer Epidemiol Biomarkers Prev 15 2006 1998-2001.
102. Gonzalez CA., Pera G., Agudo A., et al. Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) Int J Cancer 118 2006 2559-2566.
103. Freedman ND., Subar AF., Hollenbeck AR., et al. Fruit and vegetable intake and gastric cancer risk in a large United States prospective cohort study Cancer Causes Control 19 2008 459-467.
104. Tavani A., La Vecchia C., Gallus S., et al. Red meat intake and cancer risk: A study in Italy Int J Cancer 86 2000 425-428.
105. Ji BT., Chow WH., Yang G., et al. Dietary habits and stomach cancer in Shanghai, China Int J Cancer 76 1998 659-664.
106. Ward MH., Lopez-Carrillo L Dietary factors and the risk of gastric cancer in Mexico City Am J Epidemiol 149 1999 925-932.
107. Ito LS., Inoue M., Tajima K., et al. Dietary factors and the risk of gastric cancer among Japanese women: A comparison between the differentiated and non-differentiated subtypes Ann Epidemiol 2003 1324-1331.
108. Botterweck AA., van den Brandt PA., Goldbohm RA Vitamins, carotenoids, dietary fiber, and the risk of gastric carcinoma: Results from a prospective study after 6.3 years of follow-up Cancer 88 2000 737-748.
109. Ekstrom AM., Serafini M., Nyren O., et al. Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: A population-based case-control study in Sweden Int J Cancer 87 2000 133-140.
110. Kuper H., Boffetta P., Adami HO Tobacco use and cancer causation: Association by tumour type J Intern Med 252 2002 206-224.
111. Gonzalez CA., Pera G., Agudo A., et al. Smoking and the risk of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC) Int J Cancer 107 2003 629-634.
112. Sung NY., Choi KS., Park EC., et al. Smoking, alcohol and gastric cancer risk in Korean men: The National Health Insurance Corporation Study Br J Cancer 97 2007 700-704.
113. Sjodahl K., Lu Y., Nilsen TI., et al. Smoking and alcohol drinking in relation to risk of gastric cancer: A population-based, prospective cohort study Int J Cancer 120 2007 128-132.
114. Ladeiras-Lopes R., Pereira AK., Nogueira A., et al. Smoking and gastric cancer: Systematic review and meta-analysis of cohort studies Cancer Causes Control 19 2008 689-701.
115. Zendehdel K., Nyren O., Luo J., et al. Risk of gastroesophageal cancer among smokers and users of Scandinavian moist snuff Int J Cancer 122 2008 1095-1099.
116. Stenstrom B., Zhao CM., Rogers AB., et al. Swedish moist snuff accelerates gastric cancer development in Helicobacter pylori-infected wild-type and gastrin transgenic mice Carcinogenesis 28 2007 2041-2046.
117. Freedman ND., Abnet CC., Leitzmann MF., et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes Am J Epidemiol 165 2007 1424-1433.
118. Larsson SC., Giovannucci E., Wolk A Alcoholic beverage consumption and gastric cancer risk: a prospective population-based study in women Int J Cancer 120 2007 373-377.
119. Gammon MD., Schoenberg JB., Ahsan H., et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia J Natl Cancer Inst 89 1997 1277-1284.
120. Renehan AG., Tyson M., Egger M., et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies Lancet 371 2008 569-578.
121. Abnet CC., Freedman ND., Hollenbeck AR., et al. A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma Eur J Cancer 44 2008 465-471.
122. Merry AH., Schouten LJ., Goldbohm RA., van den Brandt PA Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: A prospective cohort study Gut 56 2007 1503-1511.
123. MacInnis RJ., English DR., Hopper JL., Giles GG Body size and composition and the risk of gastric and oesophageal adenocarcinoma Int J Cancer 118 2006 2628-2631.
124. Chow WH., Blot WJ., Vaughan TL., et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia J Natl Cancer Inst 90 1998 150-155.
125. Lindblad M., Rodriguez LA., Lagergren J Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study Cancer Causes Control 16 2005 285-294.
126. Zanghieri G., Di Gregorio C., Sacchetti C., et al. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry Cancer 66 1990 2047-2051.
127. Brenner H., Arndt V., Sturmer T., et al. Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma Cancer 88 2000 274-279.
128. Parsonnet J When heredity is infectious Gastroenterology 118 2000 222-224.
129. Leung WK., Ng EK., Chan WY., et al. Risk factors associated with the development of intestinal metaplasia in first-degree relatives of gastric cancer patients Cancer Epidemiol Biomarkers Prev 14 2005 2982-2986.
130. Yatsuya H., Toyoshima H., Tamakoshi A., et al. Individual and joint impact of family history and Helicobacter pylori infection on the risk of stomach cancer: a nested case-control study Br J Cancer 91 2004 929-934.
131. Lichtenstein P., Holm NV., Verkasalo PK., et al. Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark, and Finland N Engl J Med 343 2000 78-85.
132. Chang YW., Han YS., Lee DK., et al. Role of Helicobacter pylori infection among offspring or siblings of gastric cancer patients Int J Cancer 101 2002 469-474.
133. El-Omar EM., Oien K., Murray LS., et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori Gastroenterology 118 2000 22-30.
134. Stoicov C., Whary M., Rogers AB., et al. Coinfection modulates inflammatory responses and clinical outcome of Helicobacter felis and Toxoplasma gondii infections J Immunol 173 2004 3329-3336.
135. El-Omar EM., Carrington M., Chow WH., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer Nature 404 2000 398-402.
136. Figueiredo C., Machado JC., Pharoah P., et al. Helicobacter pylori and interleukin 1 genotyping: An opportunity to identify high-risk individuals for gastric carcinoma J Natl Cancer Inst 94 2002 1680-1687.
137. Furuta T., El-Omar EM., Xiao F., et al. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan Gastroenterology 123 2002 92-105.
138. Machado JC., Figueiredo C., Canedo P., et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma Gastroenterology 125 2003 364-371.
139. Zeng ZR., Hu PJ., Hu S., et al. Association of interleukin 1B gene polymorphism and gastric cancers in high and low prevalence regions in China Gut 52 2003 1684-1689.
140. Rad R., Prinz C., Neu B., et al. Synergistic effect of Helicobacter pylori virulence factors and interleukin-1 polymorphisms for the development of severe histological changes in the gastric mucosa J Infect Dis 188 2003 272-281.
141. Hwang IR., Hsu PI., Peterson LE., et al. Interleukin-6 genetic polymorphisms are not related to Helicobacter pylori-associated gastroduodenal diseases Helicobacter 8 2003 142-148.
142. Tu S., Bhagat G., Cui G., et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice Cancer Cell 14 2008 408-419.
143. El-Omar EM., Rabkin CS., Gammon MD., et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms Gastroenterology 124 2003 1193-1201.
144. Hold GL., Rabkin CS., Chow WH., et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors Gastroenterology 132 2007 905-912.
145. Guilford P., Hopkins J., Harraway J., et al. E-cadherin germline mutations in familial gastric cancer Nature 392 1998 402-405.
146. Richards FM., McKee SA., Rajpar MH., et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer Hum Mol Genet 8 1999 607-610.
147. Shinmura K., Kohno T., Takahashi M., et al. Familial gastric cancer: clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations Carcinogenesis 20 1999 1127-1131.
148. Kaurah P., MacMillan A., Boyd N., et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer JAMA 297 2007 2360-2372.
149. Lynch HT., Kaurah P., Wirtzfeld D., et al. Hereditary diffuse gastric cancer: Diagnosis, genetic counseling, and prophylactic total gastrectomy Cancer 112 2008 2655-2663.
150. Pharoah PD., Guilford P., Caldas C Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families Gastroenterology 121 2001 1348-1353.
151. Masciari S., Larsson N., Senz J., et al. Germline E-cadherin mutations in familial lobular breast cancer J Med Genet 44 2007 726-731.
152. Schrader KA., Masciari S., Boyd N., et al. Hereditary diffuse gastric cancer: Association with lobular breast cancer Fam Cancer 7 2008 73-82.
153. Zwick A., Munir M., Ryan CK., et al. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli Gastroenterology 113 1997 659-663.
154. Bianchi LK., Burke CA., Bennett AE., et al. Fundic gland polyp dysplasia is common in familial adenomatous polyposis Clin Gastroenterol Hepatol 6 2008 180-185.
155. Attard TM., Cuffari C., Tajouri T., et al. Multicenter experience with upper gastrointestinal polyps in pediatric patients with familial adenomatous polyposis Am J Gastroenterol 99 2004 681-686.
156. Aarnio M., Salovaara R., Aaltonen LA., et al. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome Int J Cancer 74 1997 551-555.
157. Howe JR., Mitros FA., Summers RW The risk of gastrointestinal carcinoma in familial juvenile polyposis Ann Surg Oncol 5 1998 751-756.
158. Coburn MC., Pricolo VE., DeLuca FG., Bland KI Malignant potential in intestinal juvenile polyposis syndromes Ann Surg Oncol 2 1995 386-391.
159. Kimura Y., Noguchi T., Kawahara K., et al. Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: Gain of 20q and loss of 18q are associated with tumor progression Mod Pathol 17 2004 1328-1337.
160. Kim JH., Takahashi T., Chiba I., et al. Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines J Natl Cancer Inst 83 1991 938-943.
161. Victor T., Du Toit R., Jordaan AM., et al. No evidence for point mutations in codons 12, 13, and 61 of the ras gene in a high-incidence area for esophageal and gastric cancers Cancer Res 50 1990 4911-4914.
162. Han S., Kim HY., Park K., et al. Expression of p27Kip1 and cyclin D1 proteins is inversely correlated and is associated with poor clinical outcome in human gastric cancer J Surg Oncol 71 1999 147-154.
163. Kim DH., Lee HI., Nam ES., et al. Reduced expression of the cell-cycle inhibitor p27Kip1 is associated with progression and lymph node metastasis of gastric carcinoma Histopathology 36 2000 245-251.
164. Takano Y., Kato Y., van Diest PJ., et al. Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases Am J Pathol 156 2000 585-594.
165. Myung N., Kim MR., Chung IP., et al. Loss of p16 and p27 is associated with progression of human gastric cancer Cancer Lett 153 2000 129-136.
166. Shim YH., Kang GH., Ro JY Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas Lab Invest 80 2000 689-695.
167. Schneider BG., Gulley ML., Eagan P., et al. Loss of p16/CDKN2A tumor suppressor protein in gastric adenocarcinoma is associated with Epstein-Barr virus and anatomic location in the body of the stomach Hum Pathol 31 2000 45-50.
168. Tsujie M., Yamamoto H., Tomita N., et al. Expression of tumor suppressor gene p16(INK4) products in primary gastric cancer Oncology 58 2000 126-136.
169. Stemmermann G., Heffelfinger SC., Noffsinger A., et al. The molecular biology of esophageal and gastric cancer and their precursors: Oncogenes, tumor suppressor genes, and growth factors Hum Pathol 25 1994 968-981.
170. Samuels Y., Wang Z., Bardelli A., et al. High frequency of mutations of the PIK3CA gene in human cancers Science 304 2004 554.
171. Wang Z., Shen D., Parsons DW., et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers Science 304 2004 1164-1166.
172. Park WS., Oh RR., Park JY., et al. Somatic mutations of the trefoil factor family 1 gene in gastric cancer Gastroenterology 119 2000 691-698.
173. Li QL., Ito K., Sakakura C., et al. Causal relationship between the loss of RUNX3 expression and gastric cancer Cell 109 2002 113-124.
174. Yio X., Diamond M., Zhang JY., et al. Trefoil factor family-1 mutations enhance gastric cancer cell invasion through distinct signaling pathways Gastroenterology 130 2006 1696-1706.
175. Ito K., Lim AC., Salto-Tellez M., et al. RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis Cancer Cell 14 2008 226-237.
176. Mironov NM., Aguelon MA., Potapova GI., et al. Alterations of (CA)n DNA repeats and tumor suppressor genes in human gastric cancer Cancer Res 54 1994 41-44.
177. Rhyu MG., Park WS., Meltzer SJ Microsatellite instability occurs frequently in human gastric carcinoma Oncogene 9 1994 29-32.
178. Fang DC., Jass JR., Wang DX., et al. Infrequent loss of heterozygosity of APC/MCC and DCC genes in gastric cancer showing DNA microsatellite instability J Clin Pathol 52 1999 504-508.
179. Isogaki J., Shinmura K., Yin W., et al. Microsatellite instability and K-ras mutations in gastric adenomas, with reference to associated gastric cancers Cancer Detect Prev 23 1999 204-214.
180. Habano W., Sugai T., Nakamura SI., et al. Microsatellite instability and mutation of mitochondrial and nuclear DNA in gastric carcinoma Gastroenterology 118 2000 835-841.
181. Leung WK., Kim JJ., Kim JG., et al. Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer Am J Pathol 156 2000 537-543.
182. Yamamoto H., Perez-Piteira J., Yoshida T., et al. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features Gastroenterology 116 1999 1348-1357.
183. Paulson TG., Wright FA., Parker BA., et al. Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer Cancer Res 56 1996 4021-4026.
184. Keller G., Vogelsang H., Becker I., et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation Am J Pathol 155 1999 337-342.
185. Yoon KA., Ku JL., Yang HK., et al. Germline mutations of E-cadherin gene in Korean familial gastric cancer patients J Hum Genet 44 1999 177-180.
186. Xiangming C., Hokita S., Natsugoe S., et al. Co-occurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer Oncology 57 1999 131-137.
187. Kawanishi K., Doki Y., Shiozaki H., et al. Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers Am J Clin Pathol 113 2000 266-274.
188. Shiozaki H., Oka H., Inoue M., et al. E-cadherin mediated adhesion system in cancer cells Cancer 77 1996 1605-1613.
189. Tamura G., Yin J., Wang S., et al. E-cadherin gene promoter hypermethylation in primary human gastric carcinomas J Natl Cancer Inst 92 2000 569-573.
190. Batlle E., Henderson JT., Beghtel H., et al. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB Cell 111 2002 251-263.
191. Ouko L., Ziegler TR., Gu LH., et al. Wnt11 signaling promotes proliferation, transformation, and migration of IEC6 intestinal epithelial cells J Biol Chem 279 2004 26707-26715.
192. Yu J., Ebert MP., Miehlke S., et al. alpha-catenin expression is decreased in human gastric cancers and in the gastric mucosa of first degree relatives Gut 46 2000 639-644.
193. Jiang Y., Jahagirdar BN., Reinhardt RL., et al. Pluripotency of mesenchymal stem cells derived from adult marrow Nature 418 2002 41-49.
194. Petersen BE., Bowen WC., Patrene KD., et al. Bone marrow as a potential source of hepatic oval cells Science 284 1999 1168-1170.
195. Krause DS., Theise ND., Collector MI., et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell Cell 105 2001 369-377.
196. Schwartz RE., Reyes M., Koodie L., et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells J Clin Invest 109 2002 1291-1302.
197. Houghton J., Stoicov C., Nomura S., et al. Gastric cancer originating from bone marrow-derived cells Science 306 2004 1568-1571.
198. Dixon MF., Genta RM., Yardley JH., Correa P Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of Gastritis, Houston 1994 Am J Surg Pathol 20 1996 1161-1181.
199. Lahner E., Bordi C., Cattaruzza MS., et al. Long-term follow-up in atrophic body gastritis patients: Atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection Aliment Pharmacol Ther 22 2005 471-481.
200. Kokkola A., Sjoblom SM., Haapiainen R., et al. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study Scand J Gastroenterol 33 1998 88-92.
201. Siurala M., Lehtola J., Ihamaki T Atrophic gastritis and its sequelae. Results of 19-23 years’ follow-up examinations Scand J Gastroenterol 9 1974 441-446.
202. de Vries AC., Haringsma J., Kuipers EJ The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection Helicobacter 12 2007 1-15.
203. Kato I., Tominaga S., Ito Y., et al. A prospective study of atrophic gastritis and stomach cancer risk Jpn J Cancer Res 83 1992 1137-1142.
204. Tatsuta M., Iishi H., Nakaizumi A., et al. Fundal atrophic gastritis as a risk factor for gastric cancer Int J Cancer 53 1993 70-74.
205. Cassaro M., Rugge M., Gutierrez O., et al. Topographic patterns of intestinal metaplasia and gastric cancer Am J Gastroenterol 95 2000 1431-1438.
206. Kuipers EJ., Uyterlinde AM., Pena AS., et al. Long-term sequelae of Helicobacter pylori gastritis Lancet 345 1995 1525-1528.
207. Asaka M., Sugiyama T., Nobuta A., et al. Atrophic gastritis and intestinal metaplasia in Japan: Results of a large multicenter study Helicobacter 6 2001 294-299.
208. Schafer LW., Larson DE., Melton LJ 3rd., et al. Risk of development of gastric carcinoma in patients with pernicious anemia: a population-based study in Rochester, Minnesota Mayo Clin Proc 60 1985 444-448.
209. Sobala GM., Schorah CJ., Sanderson M., et al. Ascorbic acid in the human stomach Gastroenterology 97 1989 357-363.
210. Wang TC., Dangler CA., Chen D., et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer Gastroenterology 118 2000 36-47.
211. Watson SA., Grabowska AM., El-Zaatari M., Takhar A Gastrin-Active participant or bystander in gastric carcinogenesis? Nat Rev Cancer 6 2006 936-946.
212. Jass JR., Filipe MI The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma Histochem J 13 1981 931-939.
213. Leung WK., Sung JJ Review article: Intestinal metaplasia and gastric carcinogenesis Aliment Pharmacol Ther 16 2002 1209-1216.
214. Rokkas T., Filipe MI., Sladen GE Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up Gut 32 1991 1110-1113.
215. Rugge M., Correa P., Dixon MF., et al. Gastric dysplasia: The Padova international classification Am J Surg Pathol 24 2000 167-176.
216. de Vries AC., Kuipers EJ Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies Helicobacter 12 Suppl 2 2007 22-31.
217. You WC., Blot WJ., Li JY., et al. Precancerous gastric lesions in a population at high risk of stomach cancer Cancer Res 53 1993 1317-1321.
218. Rugge M., Farinati F., Di Mario F., et al. Gastric epithelial dysplasia: A prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia Hum Pathol 22 1991 1002-1008.
219. Di Gregorio C., Morandi P., Fante R., De Gaetani C Gastric dysplasia. A follow-up study Am J Gastroenterol 88 1993 1714-1719.
220. Rugge M., Cassaro M., Di Mario F., et al. The long term outcome of gastric non-invasive neoplasia Gut 52 2003 1111-1116.
221. de Vries AC., van Grieken NC., Looman CW., et al. Gastric cancer risk in patients with premalignant gastric lesions: A nationwide cohort study in the Netherlands Gastroenterology 134 2008 945-952.
222. Lansdown M., Quirke P., Dixon MF., et al. High grade dysplasia of the gastric mucosa: A marker for gastric carcinoma Gut 31 1990 977-983.
223. Kokkola A., Haapiainen R., Laxen F., et al. Risk of gastric carcinoma in patients with mucosal dysplasia associated with atrophic gastritis: a follow up study J Clin Pathol 49 1996 979-984.
224. Voutilainen M., Mantynen T., Kunnamo I., et al. Impact of clinical symptoms and referral volume on endoscopy for detecting peptic ulcer and gastric neoplasms Scand J Gastroenterol 38 2003 109-113.
225. Burt RW Gastric fundic gland polyps Gastroenterology 125 2003 1462-1469.
226. Borch K., Skarsgard J., Franzen L., et al. Benign gastric polyps: morphological and functional origin Dig Dis Sci 48 2003 1292-1297.
227. Jalving M., Koornstra JJ., Wesseling J., et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy Aliment Pharmacol Ther 24 2006 1341-1348.
228. Zea-Iriarte WL., Sekine I., Itsuno M., et al. Carcinoma in gastric hyperplastic polyps. A phenotypic study Dig Dis Sci 41 1996 377-386.
229. Kamiya T., Morishita T., Asakura H., et al. Long-term follow-up study on gastric adenoma and its relation to gastric protruded carcinoma Cancer 50 1982 2496-2503.
230. Muehldorfer SM., Stolte M., Martus P., et al. Diagnostic accuracy of forceps biopsy versus polypectomy for gastric polyps: A prospective multicentre study Gut 50 2002 465-470.
231. Caygill CP., Hill MJ., Kirkham JS., Northfield TC Mortality from gastric cancer following gastric surgery for peptic ulcer Lancet 1 1986 929-931.
232. Viste A., Bjornestad E., Opheim P., et al. Risk of carcinoma following gastric operations for benign disease. A historical cohort study of 3470 patients Lancet 2 1986 502-505.
233. Lundegardh G., Adami HO., Helmick C., et al. Stomach cancer after partial gastrectomy for benign ulcer disease N Engl J Med 319 1988 195-200.
234. Dubrow R Gastric cancer following peptic ulcer surgery J Natl Cancer Inst 85 1993 1268-1270.
235. Domellof L., Eriksson S., Janunger KG Carcinoma and possible precancerous changes of the gastric stump after billroth II resection Gastroenterology 73 1977 462-468.
236. Greenlee HB., Vivit R., Paez J., Dietz A Bacterial flora of the jejunum following peptic ulcer surgery Arch Surg 102 1971 260-265.
237. Dewar P., Dixon MF., Johnston D Bile reflux and degree of gastritis in patients with gastric ulcer: Before and after operation J Surg Res 37 1984 277-284.
238. MacDonald WC., Owen DA Gastric carcinoma after surgical treatment of peptic ulcer: An analysis of morphologic features and a comparison with cancer in the nonoperated stomach Cancer 91 2001 1732-1738.
239. Hansson LE., Nyren O., Hsing AW., et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease N Engl J Med 335 1996 242-249.
240. Molloy RM., Sonnenberg A Relation between gastric cancer and previous peptic ulcer disease Gut 40 1997 247-252.
241. Case records of the Massachusetts General Hospital. Case 2-1988. A 55-year-old man with innumerable gastric polyps and recent melena N Engl J Med 318 1988 100-109.
242. Scharschmidt BF The natural history of hypertrophic gastrophy (Menetrier’s disease). Report of a case with 16 year follow-up and review of 120 cases from the literature Am J Med 63 1977 644-652.
243. Wood MG., Bates C., Brown RC., Losowsky MS Intramucosal carcinoma of the gastric antrum complicating Menetrier’s disease J Clin Pathol 36 1983 1071-1075.
244. Leung WK., Wu MS., Kakugawa Y., et al. Screening for gastric cancer in Asia: Current evidence and practice Lancet Oncol 9 2008 279-287.
245. Watanabe H., Mai M., Shimoda T., et al. Meeting report of the 72nd Japanese Gastric Cancer Congress Gastric Cancer 3 2000 1-8.
246. Kunisaki C., Ishino J., Nakajima S., et al. Outcomes of mass screening for gastric carcinoma Ann Surg Oncol 13 2006 221-228.
247. Lee KJ., Inoue M., Otani T., et al. Gastric cancer screening and subsequent risk of gastric cancer: A large-scale population-based cohort study, with a 13-year follow-up in Japan Int J Cancer 118 2006 2315-2321.
248. Mizoue T., Yoshimura T., Tokui N., et al. Prospective study of screening for stomach cancer in Japan Int J Cancer 106 2003 103-107.
249. Miki K Gastric cancer screening using the serum pepsinogen test method Gastric Cancer 9 2006 245-253.
250. Watabe H., Mitsushima T., Yamaji Y., et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: A prospective endoscopic cohort study Gut 54 2005 764-768.
251. Dan YY., So JB., Yeoh KG Endoscopic screening for gastric cancer Clin Gastroenterol Hepatol 4 2006 709-716.
252. Rogers AB., Fox JG Inflammation and cancer. I. Rodent models of infectious gastrointestinal and liver cancer Am J Physiol Gastrointest Liver Physiol 286 2004 G361-G366.
253. Moss SF The carcinogenic effect of H. pylori on the gastric epithelial cell J Physiol Pharmacol 50 1999 847-856.
254. Shimizu N., Ikehara Y., Inada K., et al. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils Cancer Res 60 2000 1512-1514.
255. Nozaki K., Shimizu N., Ikehara Y., et al. Effect of early eradication on Helicobacter pylori-related gastric carcinogenesis in Mongolian gerbils Cancer Sci 94 2003 235-239.
256. Nozaki K., Shimizu N., Tsukamoto T., et al. Reversibility of heterotopic proliferative glands in glandular stomach of Helicobacter pylori-infected Mongolian gerbils on eradication Jpn J Cancer Res 93 2002 374-381.
257. Keto Y., Ebata M., Okabe S Gastric mucosal changes induced by long term infection with Helicobacter pylori in Mongolian gerbils: Effects of bacteria eradication J Physiol Paris 95 2001 429-436.
258. Zivny J., Wang TC., Yantiss R., et al. Role of therapy or monitoring in preventing progression to gastric cancer J Clin Gastroenterol 36 5 Suppl 2003 S50-S60.
259. Correa P., Fontham ET., Bravo JC., et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy J Natl Cancer Inst 92 2000 1881-1888.
260. Sung JJ., Lin SR., Ching JY., et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: A prospective, randomized study Gastroenterology 119 2000 7-14.
261. Wong BC., Lam SK., Wong WM., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial Jama 291 2004 187-194.
262. Ley C., Mohar A., Guarner J., et al. Helicobacter pylori eradication and gastric preneoplastic conditions: A randomized, double-blind, placebo-controlled trial Cancer Epidemiol Biomarkers Prev 13 2004 4-10.
263. Leung WK., Lin SR., Ching JY., et al. Factors predicting progression of gastric intestinal metaplasia: Results of a randomised trial on Helicobacter pylori eradication Gut 53 2004 1244-1249.
264. Fukase K., Kato M., Kikuchi S., et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial Lancet 372 2008 392-397.
265. Takenaka R., Okada H., Kato J., et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type Aliment Pharmacol Ther 25 2007 805-812.
266. Dixon MF Prospects for intervention in gastric carcinogenesis: reversibility of gastric atrophy and intestinal metaplasia Gut 49 2001 2-4.
267. Parsonnet J., Harris RA., Hack HM., Owens DK Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: A mandate for clinical trials Lancet 348 1996 150-154.
268. Mason J., Axon AT., Forman D., et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: A Markov model using economic data from a randomized controlled trial Aliment Pharmacol Ther 16 2002 559-568.
269. Federico A., Morgillo F., Tuccillo C., et al. Chronic inflammation and oxidative stress in human carcinogenesis Int J Cancer 121 2007 2381-2386.
270. Jenab M., Riboli E., Ferrari P., et al. Plasma and dietary carotenoid, retinol and tocopherol levels and the risk of gastric adenocarcinomas in the European prospective investigation into cancer and nutrition Br J Cancer 95 2006 406-415.
271. Jenab M., Riboli E., Ferrari P., et al. Plasma and dietary vitamin C levels and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) Carcinogenesis 27 2006 2250-2257.
272. Persson C., Sasazuki S., Inoue M., et al. Plasma levels of carotenoids, retinol and tocopherol and the risk of gastric cancer in Japan: A nested case-control study Carcinogenesis 29 2008 1042-1048.
273. Ja Kim H., Lee SS., Choi BY., Kim MK Nitrate intake relative to antioxidant vitamin intake affects gastric cancer risk: A case-control study in Korea Nutr Cancer 59 2007 185-191.
274. Larsson SC., Bergkvist L., Naslund I., et al. Vitamin A, retinol, and carotenoids and the risk of gastric cancer: A prospective cohort study Am J Clin Nutr 85 2007 497-503.
275. Plummer M., Vivas J., Lopez G., et al. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: A randomized trial in a high-risk population J Natl Cancer Inst 99 2007 137-146.
276. You WC., Brown LM., Zhang L., et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions J Natl Cancer Inst 98 2006 974-983.
277. Omenn GS., Goodman GE., Thornquist MD., et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease N Engl J Med 334 1996 1150-1155.
278. Howe LR., Dannenberg AJ A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer Semin Oncol 29 3 Suppl 11 2002 111-119.
279. Saukkonen K., Rintahaka J., Sivula A., et al. Cyclooxygenase-2 and gastric carcinogenesis Apmis 111 2003 915-925.
280. Ristimaki A., Honkanen N., Jankala H., et al. Expression of cyclooxygenase-2 in human gastric carcinoma Cancer Res 57 1997 1276-1280.
281. Murata H., Kawano S., Tsuji S., et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma Am J Gastroenterol 94 1999 451-455.
282. Sawaoka H., Kawano S., Tsuji S., et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice Am J Physiol 274 1998 G1061-G1067.
283. Yamamoto H., Itoh F., Fukushima H., et al. Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability Int J Cancer 84 1999 400-403.
284. van Rees BP., Saukkonen K., Ristimaki A., et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach J Pathol 196 2002 171-179.
285. Sung JJ., Leung WK., Go MY., et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions Am J Pathol 157 2000 729-735.
286. Akre K., Ekstrom AM., Signorello LB., et al. Aspirin and risk for gastric cancer: A population-based case-control study in Sweden Br J Cancer 84 2001 965-968.
287. Duan L., Wu AH., Sullivan-Halley J., Bernstein L Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County Cancer Epidemiol Biomarkers Prev 17 2008 126-134.
288. Wang WH., Huang JQ., Zheng GF., et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: A systematic review and meta-analysis J Natl Cancer Inst 95 2003 1784-1791.
289. Lindblad M., Lagergren J., Garcia Rodriguez LA Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer Cancer Epidemiol Biomarkers Prev 14 2005 444-450.
290. Leung WK., Ng EK., Chan FK., et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial Clin Cancer Res 12 2006 4766-4772.
291. Masuda M., Suzui M., Weinstein IB Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines Clin Cancer Res 7 2001 4220-4229.
292. Ahmad N., Feyes DK., Nieminen AL., Agarwal R., Mukhtar H Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells J Natl Cancer Inst 89 1997 1881-1886.
293. Masuda M., Suzui M., Lim JT., Weinstein IB Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells Clin Cancer Res 9 2003 3486-3491.
294. Saffari Y., Sadrzadeh SM Green tea metabolite EGCG protects membranes against oxidative damage in vitro Life Sci 74 2004 1513-1518.
295. D’Alessandro T., Prasain J., Benton MR., et al. Polyphenols, inflammatory response, and cancer prevention: chlorination of isoflavones by human neutrophils J Nutr 133 11 Suppl 1 2003 3773S-3777S.
296. Yu GP., Hsieh CC., Wang LY., et al. Green-tea consumption and risk of stomach cancer: A population-based case-control study in Shanghai, China Cancer Causes Control 6 1995 532-538.
297. Inoue M., Tajima K., Hirose K., et al. Tea and coffee consumption and the risk of digestive tract cancers: Data from a comparative case-referent study in Japan Cancer Causes Control 9 1998 209-216.
298. Ji BT., Chow WH., Yang G., et al. The influence of cigarette smoking, alcohol, and green tea consumption on the risk of carcinoma of the cardia and distal stomach in Shanghai, China Cancer 77 1996 2449-2457.
299. Tsubono Y., Nishino Y., Komatsu S., et al. Green tea and the risk of gastric cancer in Japan N Engl J Med 344 2001 632-636.
300. Sasazuki S., Inoue M., Hanaoka T., et al. Green tea consumption and subsequent risk of gastric cancer by subsite: the JPHC Study Cancer Causes Control 15 2004 483-491.
301. Tucker HJ., Snape WJ Jr., Cohen S Achalasia secondary to carcinoma: Manometric and clinical features Ann Intern Med 89 1978 315-318.
302. Wakashin M., Wakashin Y., Iesato K., et al. Association of gastric cancer and nephrotic syndrome. An immunologic study in three patients Gastroenterology 78 1980 749-756.
303. Gragasin-Saviano L., Isaacson E., Stuck RM Pedal gangrene secondary to disseminated intravascular coagulation with gastric carcinoma J Am Podiatr Med Assoc 92 2002 149-152.
304. Croft PB., Wilkinson M The incidence of carcinomatous neuromyopathy in patients with various types of carcinoma Brain 88 1965 427-434.
305. Yeh JS., Munn SE., Plunkett TA., et al. Coexistence of acanthosis nigricans and the sign of Leser-Trelat in a patient with gastric adenocarcinoma: A case report and literature review J Am Acad Dermatol 42 2000 357-362.
306. Dupont JB Jr., Lee JR., Burton GR., Cohn I Jr Adenocarcinoma of the stomach: Review of 1, 497 cases Cancer 41 1978 941-947.
307. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007 CA Cancer J Clin 57 2007 43-66.
308. Hess KR., Varadhachary GR., Taylor SH., et al. Metastatic patterns in adenocarcinoma Cancer 106 2006 1624-1633.
309. Hornung M., Vogel P., Schubert T., Schlitt HJ., Bolder U A case of virilization induced by a Krukenberg tumor from gastric cancer World J Surg Oncol 6 2008 19.
310. Massarotti M., Ciocia G., Ceriani R., et al. Metastatic gastric cancer presenting with shoulder-hand syndrome: A case report J Med Case Reports 2 2008 240.
311. Yunker JJ., Vicinanzo MG., Braswell RA., et al. Unusual presentation of gastric adenocarcinoma metastatic to the orbit Ophthal Plast Reconstr Surg 22 2006 490-491.
312. Saornil MA., Blanco G., Sarasa JL., et al. Isolated metastasis of gastric adenocarcinoma to the retina: First presentation of systemic disease Acta Ophthalmol Scand 82 2004 86-88.
313. Farley DR., Donohue JH Early gastric cancer Surg Clin North Am 72 1992 401-421.
314. Talley NJ American Gastroenterological Association medical position statement: Evaluation of dyspepsia Gastroenterology 129 2005 1753-1755.
315. Tanaka K., Toyoda H., Kadowaki S., et al. Surface pattern classification by enhanced-magnification endoscopy for identifying early gastric cancers Gastrointest Endosc 67 2008 430-437.
316. Kato M., Kaise M., Yonezawa J., et al. Autofluorescence endoscopy versus conventional white light endoscopy for the detection of superficial gastric neoplasia: A prospective comparative study Endoscopy 39 2007 937-941.
317. Kitabatake S., Niwa Y., Miyahara R., et al. Confocal endomicroscopy for the diagnosis of gastric cancer in vivo Endoscopy 38 2006 1110-1114.
318. The Paris endoscopic classification of superficial neoplastic lesions: Esophagus, stomach, and colon Gastrointest Endosc 58 2003 S3-28.
319. Archer AG., Grant DC Recent developments in diagnostic radiology of primary and recurrent gastric cancer Cancer Treat Res 55 1991 107-131.
320. Shin KS., Kim SH., Han JK., et al. Three-dimensional MDCT gastrography compared with axial CT for the detection of early gastric cancer J Comput Assist Tomogr 31 2007 741-749.
321. Kitahara F., Kobayashi K., Sato T., et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations Gut 44 1999 693-697.
322. Westerveld BD., Pals G., Lamers CB., et al. Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels Cancer 59 1987 952-958.
323. Ohata H., Oka M., Yanaoka K., et al. Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography Cancer Sci 96 2005 713-720.
324. Mukoubayashi C., Yanaoka K., Ohata H., et al. Serum pepsinogen and gastric cancer screening Intern Med 46 2007 261-266.
325. Fernandez-Fernandez L., Tejero E., Tieso A., et al. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer Int Surg 81 1996 400-402.
326. Takahashi Y., Takeuchi T., Sakamoto J., et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: A prospective clinical study Gastric Cancer 6 2003 142-145.
327. Li X., Yue ZC., Zhang YY., et al. Elevated serum level and gene polymorphisms of TGF-beta1 in gastric cancer J Clin Lab Anal 22 2008 164-171.
328. Goral V., Yesilbagdan H., Kaplan A., Sit D Evaluation of CA 72-4 as a new tumor marker in patients with gastric cancer Hepatogastroenterology 54 2007 1272-1275.
329. Kumar Y., Tapuria N., Kirmani N., Davidson BR Tumour M2-pyruvate kinase: a gastrointestinal cancer marker Eur J Gastroenterol Hepatol 19 2007 265-276.
330. Tanaka K., Miki C., Wakuda R., et al. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma Scand J Gastroenterol 39 2004 754-760.
331. Fujiwara M., Kodera Y., Misawa K., et al. Longterm outcomes of early-stage gastric carcinoma patients treated with laparoscopy-assisted surgery J Am Coll Surg 206 2008 138-143.
332. Kitano S., Shiraishi N., Uyama I., et al. A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan Ann Surg 245 2007 68-72.
333. Borie F., Plaisant N., Millat B., et al. Appropriate gastric resection with lymph node dissection for early gastric cancer Ann Surg Oncol 11 2004 512-517.
334. Yamashita K., Sakuramoto S., Kikuchi S., et al. Validation of staging systems for gastric cancer Gastric Cancer 11 2008 111-118.
335. Greene FL., Page DL., Fleming ID., et al. AJCC cancer staging manual6th ed 2002 Springer New York.
336. Sobin LH., Wittekind C TNM classification of malignant tumors (UICC) 1997 John Wiley New York.
337. Nicholson DA., Shorvon PJ Review article: Endoscopic ultrasound of the stomach Br J Radiol 66 1993 487-492.
338. Kwee RM., Kwee TC Imaging in local staging of gastric cancer: A systematic review J Clin Oncol 25 2007 2107-2116.
339. Yoshida S., Tanaka S., Kunihiro K., et al. Diagnostic ability of high-frequency ultrasound probe sonography in staging early gastric cancer, especially for submucosal invasion Abdom Imaging 30 2005 518-523.
340. Kuntz C., Herfarth C Imaging diagnosis for staging of gastric cancer Semin Surg Oncol 17 1999 96-102.
341. Habermann CR., Weiss F., Riecken R., et al. Preoperative staging of gastric adenocarcinoma: comparison of helical CT and endoscopic US Radiology 230 2004 465-471.
342. Polkowski M., Palucki J., Wronska E., et al. Endosonography versus helical computed tomography for locoregional staging of gastric cancer Endoscopy 36 2004 617-623.
343. Wang JY., Hsieh JS., Huang YS., et al. Endoscopic ultrasonography for preoperative locoregional staging and assessment of resectability in gastric cancer Clin Imaging 22 1998 355-359.
344. Xi WD., Zhao C., Ren GS Endoscopic ultrasonography in preoperative staging of gastric cancer: Determination of tumor invasion depth, nodal involvement and surgical resectability World J Gastroenterol 9 2003 254-257.
345. Monig SP., Zirbes TK., Schroder W., et al. Staging of gastric cancer: Correlation of lymph node size and metastatic infiltration AJR Am J Roentgenol 173 1999 365-367.
346. Yang DM., Kim HC., Jin W., et al. 64 multidetector-row computed tomography for preoperative evaluation of gastric cancer: Histological correlation J Comput Assist Tomogr 31 2007 98-103.
347. Bhandari S., Shim CS., Kim JH., et al. Usefulness of three-dimensional, multidetector row CT (virtual gastroscopy and multiplanar reconstruction) in the evaluation of gastric cancer: A comparison with conventional endoscopy, EUS, and histopathology Gastrointest Endosc 59 2004 619-626.
348. Lim JS., Yun MJ., Kim MJ., et al. CT and PET in stomach cancer: Preoperative staging and monitoring of response to therapy Radiographics 26 2006 143-156.
349. Park SR., Lee JS., Kim CG., et al. Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer Cancer 112 2008 2368-2376.
350. Patel PR., Mansfield PF., Crane CH., et al. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer Cancer 110 2007 989-995.
351. Hundahl SA., Phillips JL., Menck HR The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis Cancer 88 2000 921-932.
352. Nakagawa S., Nashimoto A., Yabusaki H Role of staging laparoscopy with peritoneal lavage cytology in the treatment of locally advanced gastric cancer Gastric Cancer 10 2007 29-34.
353. Gouzi JL., Huguier M., Fagniez PL., et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study Ann Surg 209 1989 162-166.
354. Bozzetti F., Marubini E., Bonfanti G., et al. Subtotal versus total gastrectomy for gastric cancer: Five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group Ann Surg 230 1999 170-178.
355. Cuschieri A., Weeden S., Fielding J., et al. Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Surgical Co-operative Group Br J Cancer 79 1999 1522-1530.
356. Yu W., Choi GS., Chung HY Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer Br J Surg 93 2006 559-563.
357. Hartgrink HH., van de Velde CJ., Putter H., et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial J Clin Oncol 22 2004 2069-2077.
358. Van Cutsem E., Van de Velde C., Roth A., et al. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group Eur J Cancer 44 2008 182-194.
359. Yamao T., Shirao K., Ono H., et al. Risk factors for lymph node metastasis from intramucosal gastric carcinoma Cancer 77 1996 602-606.
360. Soetikno R., Kaltenbach T., Yeh R., Gotoda T Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract J Clin Oncol 23 2005 4490-4498.
361. Kakushima N., Fujishiro M Endoscopic submucosal dissection for gastrointestinal neoplasms World J Gastroenterol 14 2008 2962-2967.
362. Imagawa A., Okada H., Kawahara Y., et al. Endoscopic submucosal dissection for early gastric cancer: Results and degrees of technical difficulty as well as success Endoscopy 38 2006 987-990.
363. Onozato Y., Ishihara H., Iizuka H., et al. Endoscopic submucosal dissection for early gastric cancers and large flat adenomas Endoscopy 38 2006 980-986.
364. De Vita F., Giuliani F., Galizia G., et al. Neo-adjuvant and adjuvant chemotherapy of gastric cancer Ann Oncol 18 Suppl 6 2007 vi120-vi123.
365. Earle CC., Maroun JA Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomised trials Eur J Cancer 35 1999 1059-1064.
366. Janunger KG., Hafstrom L., Glimelius B Chemotherapy in gastric cancer: A review and updated meta-analysis Eur J Surg 168 2002 597-608.
367. Di Costanzo F., Gasperoni S., Manzione L., et al. Adjuvant chemotherapy in completely resected gastric cancer: A randomized phase III trial conducted by GOIRC J Natl Cancer Inst 100 2008 388-398.
368. Bouche O., Ychou M., Burtin P., et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801) Ann Oncol 16 2005 1488-1497.
369. Cunningham D., Allum WH., Stenning SP., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 2006 11-20.
370. Macdonald JS., Smalley SR., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 2001 725-730.
371. Ajani JA., Winter K., Okawara GS., et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response J Clin Oncol 24 2006 3953-3958.
372. Yu W., Whang I., Chung HY., et al. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: Results of a prospective randomized trial World J Surg 25 2001 985-990.
373. Yonemura Y., de Aretxabala X., Fujimura T., et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: Final results of a randomized controlled study Hepatogastroenterology 48 2001 1776-1782.
374. Sautner T., Hofbauer F., Depisch D., et al. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer J Clin Oncol 12 1994 970-974.
375. Rosen HR., Jatzko G., Repse S., et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: Results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology J Clin Oncol 16 1998 2733-2738.
376. Yan TD., Black D., Sugarbaker PH., et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer Ann Surg Oncol 14 2007 2702-2713.
377. Cascinu S., Scartozzi M., Labianca R., et al. High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgrastim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) Br J Cancer 90 2004 1521-1525.
378. Schuhmacher CP., Fink U., Becker K., et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up Cancer 91 2001 918-927.
379. Cervantes A., Rosello S., Roda D., Rodriguez-Braun E The treatment of advanced gastric cancer: current strategies and future perspectives Ann Oncol 19 Suppl 5 2008 v103-v107.
380. Ross P., Nicolson M., Cunningham D., et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer J Clin Oncol 20 2002 1996-2004.
381. Ajani JA., Moiseyenko VM., Tjulandin S., et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group J Clin Oncol 25 2007 3205-3209.
382. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 2008 36-46.
383. Jeurnink SM., van Eijck CH., Steyerberg EW., et al. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review BMC Gastroenterol 7 2007 18.
384. Azab MB., Henry-Amar M., Rougier P., et al. Prognostic factors in primary gastrointestinal non-Hodgkin’s lymphoma. A multivariate analysis, report of 106 cases, and review of the literature Cancer 64 1989 1208-1217.
385. Amer MH., el-Akkad S Gastrointestinal lymphoma in adults: clinical features and management of 300 cases Gastroenterology 106 1994 846-858.
386. Kolve M., Fischbach W., Greiner A., Wilms K Differences in endoscopic and clinicopathological features of primary and secondary gastric non-Hodgkin’s lymphoma. German Gastrointestinal Lymphoma Study Group Gastrointest Endosc 49 1999 307-315.
387. Maggard MA., O’Connell JB., Ko CY Updated population-based review of carcinoid tumors Ann Surg 240 2004 117-122.
388. Burkitt MD., Pritchard DM Review article: Pathogenesis and management of gastric carcinoid tumours Aliment Pharmacol Ther 24 2006 1305-1320.
389. Katz SC., DeMatteo RP Gastrointestinal stromal tumors and leiomyosarcomas J Surg Oncol 97 2008 350-359.
390. Campoli PM., Ejima FH., Cardoso DM., et al. Metastatic cancer to the stomach Gastric Cancer 9 2006 19-25.
391. Stein L., Urban MI., O’Connell D., et al. The spectrum of human immunodeficiency virus-associated cancers in a South African black population: Results from a case-control study, 1995-2004 Int J Cancer 122 2008 2260-2265.
392. Hong HS., Ha HK., Won HJ., et al. Gastric schwannomas: Radiological features with endoscopic and pathological correlation Clin Radiol 63 2008 536-542.
393. Otsuji E., Yamaguchi T., Taniguchi H., et al. Malignant endocrine carcinoma of the stomach Hepatogastroenterology 47 2000 601-604.
394. Yang GY., Liao J., Cassai ND., et al. Parietal cell carcinoma of gastric cardia: Immunophenotype and ultrastructure Ultrastruct Pathol 27 2003 87-94.